CARsgen Therapeutics Holdings Limited, a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumours, announces that KJ-C2320, an allogeneic CAR ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback